Summary Statistics | Forced Entry | Test variables | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Panel | Study group | AIC | adj.r2 | p | CSF-autopsy (a) / Education (b) | Age-at-death (a) / Age-at-CSF (b) | AD comorbidity | Sex | Calsyntenin-1 | VAMP-2 | Neurexin-3a | GluA4 | Syntaxin-1b | Neuroligin-2 | Neurexin-2a | Thy-1 | ||||||
a) Outcome measure: Global TDP-43 | ||||||||||||||||||||||
A[CLSTN1-VAMP2] | FTLD | 119 | 0.69 | 0.003 | -0.91 | -2.91 | 3.1 | -4.8 | 2.71 | -1.28 | ||||||||||||
b) Outcome measure: MMSE | ||||||||||||||||||||||
A[CLSTN1-VAMP2] | FTLD | 273 | 0.19 | 0.03 | 1.21 | -1.9 | -0.36 | 2.41 | -2.43 | |||||||||||||
B[CLSTN1-VAMP2-GLUA4] | FTLD-Tau | 98 | 0.49 | 0.04 | -1.79 | -2.45 | -3.60 | 3.15 | 2.57 | 1.90 | ||||||||||||
FTLD-TDP | 174 | 0.02 | 0.40 | 0.93 | -1.46 | -0.23 | 0.80 | 0.91 | -0.68 | |||||||||||||
FTLD | 279 | 0.09 | 0.16 | 1.46 | -1.29 | -0.65 | 1.16 | 0.99 | -1.29 | |||||||||||||
C[GLUA4-NRX3A-STX1B] | FTLD-Tau | 131 | 0.02 | 0.45 | 1.49 | -0.55 | 0.22 | -1.59 | 1.28 | -0.57 | 0.65 | |||||||||||
FTLD-TDP | 162 | 0.40 | 0.02 | 2.54 | -3.21 | 1.33 | -3.42 | 3.71 | -2.4 | 1.69 | ||||||||||||
FTLD | 291 | 0.30 | 0.004 | 2.11 | -2.53 | 1.12 | -3.5 | 3.74 | -2.22 | 1.22 | ||||||||||||
c) Outcome measure: AUC | ||||||||||||||||||||||
FTLD-Tau vs Controls | FTLD-Tau vs AD | FTLD-TDP vs Controls | FTLD-TDP vs AD | FTLD-TDP vs FTLD-Tau | ||||||||||||||||||
Model | AUC | 95%CI | AUC | 95%CI | AUC | 95%CI | AUC | 95%CI | AUC | 95%CI | ||||||||||||
A[CLSTN1-VAMP2] | 71.1 | 56–85 | 80.1 | 66–92 | 76.9 | 64–88 | 77.2 | 63–89 | 72.6 | 57–86 | ||||||||||||
B[CLSTN1-VAMP2-GLUA4] | 71.3 | 56–85 | 75.8 | 60–89 | 82.3 | 71–93 | 81.3 | 68–92 | 83.0 | 70–94 | ||||||||||||
C[GLUA4-NRX3A-STX1B] | 64.6 | 49–79 | 79.7 | 66–91 | 65.8 | 52–79 | 66.7 | 51–82 | 70.8 | 55–84 |